ACI-3847

N/A

Report date: 2022/11/13 11:45:22
NME

Base Information

Drug NameACI-3847
Drug Alias NameACI-384718F-ACI-3847
ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive diagnostic agent
Mechanisms of ActionPositron-emission tomography enhancersRadionuclide imaging enhancersSynuclein alpha modulators
TargetsSynuclein alpha
Therapy Area/IndicationsNeurodegenerative DiseasesParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAc Immune SaBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAc Immune Sa
Inactive CompaniesN/A
Active IndicationsNeurodegenerative DiseasesParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A